What 9 Analyst Ratings Have To Say About Genmab
Portfolio Pulse from Benzinga Insights
Genmab (NASDAQ:GMAB) has been analyzed by 9 analysts over the past three months, showing a range of ratings from bullish to bearish. The average 12-month price target is $47.78, reflecting a 7.37% increase from the previous average. Key analysts have maintained their ratings, with some raising their price targets. Genmab's financial performance shows strong revenue growth but challenges in profitability and returns.
May 20, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Genmab has received mixed analyst ratings with an average 12-month price target of $47.78, indicating a 7.37% increase. Analysts have maintained their ratings, with some raising their price targets. The company shows strong revenue growth but faces challenges in profitability and returns.
The mixed analyst ratings and the increase in the average price target suggest a positive short-term outlook for Genmab. The company's strong revenue growth supports this, although challenges in profitability and returns may temper expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100